# The First Pill-Versus-Pill Trial

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/the-first-pill-versus-pill-trial

> Orforglipron beat oral semaglutide on HbA1c at every dose pairing in 1,698 adults, and produced twice the dropouts and three times the heart rate rise. Both halves are the result.

## Key points

- Orforglipron beat oral semaglutide on HbA1c at every dose pairing.
- The LOW orforglipron dose beat the HIGH semaglutide dose (−0.24%, p=0.0050).
- But 9–10% quit for side effects vs 4–5%, roughly double.
- Pulse rose 3.7–4.7 bpm vs 1.0–1.5 bpm.
- Open-label, and only ONE of these drugs requires a 30-minute fasting window.
- A diabetes HbA1c trial. Not a weight-loss result.

ACHIEVE-3 put [two oral GLP-1s](https://glpwatchdog.org/compare/drugs/foundayo-vs-rybelsus) directly against each other in 1,698 adults with type 2 diabetes, and orforglipron beat oral semaglutide on blood sugar at **every dose pairing tested**, including the low orforglipron dose against the high semaglutide dose.[1] It also produced more gastrointestinal side effects, roughly double the dropouts, and a larger rise in resting heart rate. Both halves are the result.

## What the trial did

Adults with type 2 diabetes inadequately controlled on at least 1,500 mg of metformin daily, with an HbA1c between 7.0% and 10.5% and a BMI of 25 or above, were randomized in equal quarters to orforglipron 12 mg, orforglipron 36 mg, oral semaglutide 7 mg, or oral semaglutide 14 mg, and followed for 52 weeks across 131 centers in Argentina, China, Japan, Mexico and the United States. Baseline HbA1c averaged 8.3%. The trial doses are not the strengths on the Foundayo label: Lilly’s later ACHIEVE-4 paper states that a 36 mg capsule dose is equivalent to the 17.2 mg tablet.[2]

The design first asked whether orforglipron could match semaglutide within 0.3% (non-inferiority), and tested superiority only if that was met. It was met, and superiority followed.

*ACHIEVE-3: HbA1c change at 52 weeks from a baseline of 8.3%, treatment-regimen estimand.[1]*

| Arm | HbA1c change | vs semaglutide 7 mg | vs semaglutide 14 mg |
| --- | --- | --- | --- |
| Orforglipron 12 mg | −1.71% | −0.48% (−0.65 to −0.31), p<0.0001 | −0.24% (−0.41 to −0.072), p=0.0050 |
| Orforglipron 36 mg | −1.91% | −0.68% (−0.85 to −0.50), p<0.0001 | −0.44% (−0.62 to −0.26), p<0.0001 |
| Oral semaglutide 7 mg | −1.23% | — | — |
| Oral semaglutide 14 mg | −1.47% | — | — |

Look at the first row, last column: **the low dose of orforglipron beat the high dose of semaglutide**, by 0.24 percentage points. The difference is modest but meaningful, because it is the comparison a formulary makes when deciding what to put where.

## The design problem this particular pair creates

> **The trial was open-label, and these two drugs are not equally easy to take correctly.** Oral semaglutide only absorbs if it is swallowed fasting, with no more than about four ounces of water, followed by nothing at all for 30 minutes. Orforglipron carries no food or water restriction; that is the entire point of its chemistry. Everyone in this trial knew which regimen they had drawn.

That creates a route to the result that is not pharmacology. Semaglutide’s blood level depends on a daily ritual being performed correctly; orforglipron’s does not. A gap of 0.24 to 0.68 percentage points could reflect the molecule, or the fasting window, or both, and a trial where participants know their assignment cannot separate them.

We are not claiming that is what happened. We are saying the trial cannot tell you, and that this ambiguity matters more here than in an ordinary head-to-head. The ambiguity also has a second side. If convenience is part of why orforglipron did better, that is still a real advantage to a real patient, just not the advantage the word “superior” implies.

## The cost side of the result

Gastrointestinal events hit 59% of the orforglipron 12 mg arm and 58% of the 36 mg arm, against 37% on semaglutide 7 mg and 45% on 14 mg. Most were mild to moderate. The consequential number is what people did about them.

*Tolerability and heart rate, ACHIEVE-3 at 52 weeks.[1]*

|   | Orfo 12 mg | Orfo 36 mg | Sema 7 mg | Sema 14 mg |
| --- | --- | --- | --- | --- |
| Gastrointestinal events | 59% | 58% | 37% | 45% |
| Stopped due to adverse events | 9% | 10% | 4% | 5% |
| Mean pulse increase | +3.7 bpm | +4.7 bpm | +1.0 bpm | +1.5 bpm |

> Roughly twice as many people quit orforglipron because of side effects. That is part of the finding, not a footnote to it.

The pulse difference deserves its own sentence. A rise in resting heart rate is a known class effect, but here it was more than three times larger with orforglipron than with oral semaglutide at the paired doses. [Why a GLP-1 raises your heart rate](https://glpwatchdog.org/research/glp1-heart-rate-and-palpitations) covers what the labels say about it. In a population with type 2 diabetes and a mean BMI above 25, that is a variable a cardiologist would want to know about, and it has no bearing on the HbA1c headline whatsoever.

Four deaths occurred across the trial: one in each orforglipron arm and two on semaglutide 7 mg. With 1,698 participants over a year, that is not a signal in either direction.

## What this does not tell you

- **It is not a weight-loss trial.** The endpoint was HbA1c in people with type 2 diabetes on metformin. Orforglipron’s obesity evidence is a separate trial with a separate design, and reading a diabetes HbA1c result as a weight result is the error this register calls out in sellers.
- **The comparator was 7 and 14 mg oral semaglutide**, not the higher 25 and 50 mg strengths. A different comparator arm could produce a different gap.
- **Eli Lilly funded it**, and Eli Lilly makes orforglipron. The comparator is a Novo Nordisk product. That does not invalidate a Lancet phase 3 trial; it is context every reader of an industry head-to-head is entitled to.
- **Fifty-two weeks is not a long time** for a chronic condition, and nothing here speaks to cardiovascular or kidney outcomes. Orforglipron now has a cardiovascular *safety* trial: ACHIEVE-4 compared it with insulin glargine and found its rate of serious cardiovascular events inside the prespecified safety margin (hazard ratio 0.84, 95% CI 0.59 to 1.20).[2] That rules out a large harm. It is not the outcome benefit semaglutide has shown.
- **Orforglipron is not approved for type 2 diabetes.** In the US it is sold as Foundayo for weight management only. Lilly has submitted the diabetes indication to the FDA, and no decision has been announced.[3]

For what orforglipron is and how it is labeled, see [Foundayo](https://glpwatchdog.org/research/foundayo-orforglipron-oral-glp1). For the drugs still behind it, see [the oral pipeline](https://glpwatchdog.org/research/elecoglipron-oral-glp1-pipeline), and for how side-effect burden compares across the class generally, see [which GLP-1 has the worst side effects](https://glpwatchdog.org/research/which-glp1-has-the-worst-side-effects).

## Frequently asked questions

### Is orforglipron better than oral semaglutide?

For blood sugar over 52 weeks in people with type 2 diabetes on metformin, it produced larger HbA1c reductions at every dose pairing tested, including the low orforglipron dose against the high semaglutide dose. It also caused more gastrointestinal side effects, about twice as many discontinuations, and a larger heart rate rise.

### Does this mean orforglipron causes more weight loss?

The trial does not say. Its endpoint was HbA1c in people with type 2 diabetes, not weight in people with obesity. Those are different questions with different trials behind them.

### Why does the open-label design matter here?

Oral semaglutide only absorbs if taken fasting with minimal water and nothing for 30 minutes afterward; orforglipron has no such restriction. Participants knew which they were taking, so part of the difference could be adherence to that fasting window rather than the molecules themselves. The trial cannot separate the two.

### How much did side effects differ?

Gastrointestinal events occurred in 58–59% of orforglipron participants against 37–45% on oral semaglutide, and 9–10% stopped orforglipron because of adverse events against 4–5% on semaglutide.

### What about heart rate?

Mean pulse rose 3.7 bpm on orforglipron 12 mg and 4.7 bpm on 36 mg, against 1.0 and 1.5 bpm on oral semaglutide 7 and 14 mg. At the paired doses (12 mg against 7 mg, 36 mg against 14 mg), that is more than three times larger, in a class where a heart rate rise is already expected.

## References

1. Rosenstock J, Yabe D, Cox D, et al. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. The Lancet. 2026. PMID: 41765029. https://pubmed.ncbi.nlm.nih.gov/41765029/
2. Klein KR, Wysham C, Tuttle KR, et al. Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial. The Lancet. 2026. PMID: 42815506. https://pubmed.ncbi.nlm.nih.gov/42815506/
3. Eli Lilly and Company Lilly reports second-quarter 2026 financial results (Form 8-K, Exhibit 99.1) — regulatory progress includes the submission for orforglipron for type 2 diabetes in the U.S. U.S. Securities and Exchange Commission (EDGAR). 2026. https://www.sec.gov/Archives/edgar/data/59478/000005947826000077/q226lillysalesandearningsp.htm

---

Cite as: GLP Watchdog, Nora Bissett, "The First Pill-Versus-Pill Trial", published 2026-08-20, updated 2026-10-27. https://glpwatchdog.org/research/the-first-pill-versus-pill-trial

Canonical HTML page: https://glpwatchdog.org/research/the-first-pill-versus-pill-trial

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
